Alendronic acid
- Generic Name
- Alendronic acid
- Brand Names
- Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance
- Drug Type
- Small Molecule
- Chemical Formula
- C4H13NO7P2
- CAS Number
- 66376-36-1
- Unique Ingredient Identifier
- X1J18R4W8P
- Background
Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
- Indication
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.
- Associated Conditions
- Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget’s Disease
- Associated Therapies
- -
Fosamax for Childhood Cancer Survivors
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2008-05-23
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 100
- Registration Number
- NCT00391404
- Locations
- 🇭🇰
Prince of Wales Hospital, Shatin, N.T., Hong Kong, Hong Kong
Study of Transitioning From Alendronate to Denosumab
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 504
- Registration Number
- NCT00377819
The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
- Conditions
- Osteoporosis
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2007-04-12
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 10
- Registration Number
- NCT00346190
- Locations
- 🇨🇦
Mcgill University Health center, Montreal, Quebec, Canada
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
- First Posted Date
- 2006-05-26
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1189
- Registration Number
- NCT00330460
Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
- Conditions
- Osteoporosis
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00327990
- Locations
- 🇳🇱
GSK Investigational Site, Zaandam, Netherlands
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
- Conditions
- Liver TransplantationBone ResorptionHeart Transplantation
- Interventions
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 111
- Registration Number
- NCT00297830
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 247
- Registration Number
- NCT00293813
Alendronate Osteoporosis Study
- Conditions
- Glucocorticoid-Associated Osteopenia and Osteoporosis
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00277251
Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis
- Conditions
- Non-Traumatic Osteonecrosis
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2008-02-27
- Target Recruit Count
- 60
- Registration Number
- NCT00265252
- Locations
- 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
- Conditions
- End-Stage Renal DiseaseOsteoporosis
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2009-01-05
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00261625
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.